2018
Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo
De Feyter HM, Behar KL, Corbin ZA, Fulbright RK, Brown PB, McIntyre S, Nixon TW, Rothman DL, de Graaf RA. Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Science Advances 2018, 4: eaat7314. PMID: 30140744, PMCID: PMC6105304, DOI: 10.1126/sciadv.aat7314.Peer-Reviewed Original ResearchConceptsOral intakeMetabolic imagingGlucose uptakeHigh-grade brain tumorsRat glioma modelPositron emission tomography (PET) detectionSimilar metabolic patternMetabolic imaging techniquesDeuterium metabolic imagingHigher glucose uptakeGlucose analog 2FDG-PETF-fluoroIntravenous infusionBrain tumorsGlioma modelGlucose metabolismNormal brainTomography detectionAnimal modelsMagnetic resonance spectroscopicTumor tissueHuman liverMetabolic patternsNoninvasive approach
2017
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Science Translational Medicine 2017, 9 PMID: 28148839, PMCID: PMC5435119, DOI: 10.1126/scitranslmed.aal2463.Peer-Reviewed Original ResearchConceptsIsocitrate dehydrogenase 1PARP inhibitor sensitivityPossible therapeutic strategiesHomologous recombination defectsTherapeutic strategiesTumor xenograftsInhibitor sensitivityPathologic processesSmall molecule inhibitorsIDH1/2 mutationsTumor progressionIDH2 mutationsMutant IDHPolymerase inhibitorsGlioma cellsTumor cellsHR deficiencyPARP inhibitionIDH mutationsInhibitory effectDehydrogenase 1Neomorphic activityMutant IDH1 enzymeDependent dioxygenasesMutant cells
2016
A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth
De Feyter HM, Behar KL, Rao JU, Madden-Hennessey K, Ip KL, Hyder F, Drewes LR, Geschwind JF, de Graaf RA, Rothman DL. A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. Neuro-Oncology 2016, 18: 1079-1087. PMID: 27142056, PMCID: PMC4933488, DOI: 10.1093/neuonc/now088.Peer-Reviewed Original ResearchConceptsKetone body oxidationKetogenic dietKetone bodiesGlioma modelBrain tumorsBrain tumor metabolismCortical brain tissuePlasma glucose concentrationRat glioma modelRodent glioma modelsContralateral brainRat gliomaTumor growthBrain tissueTumor metabolismBeta-hydroxybutyrate oxidationTumor cellsGliomasMR spectroscopyTumor's abilityMonocarboxylate transportersDietGlucose concentrationKetone body transportTherapy